Modus Therapeutics AB

Belkins
Modus Therapeutics AB is a Swedish drug development company developing sevuparin, which has the potential to restore blood flow in both sickle cell disease and malaria patients. Sevuparin originates from research at the Karolinska Institute and Uppsala University.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa | May 19, 2021

news image

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More

TRUMP FULFILLED A LONGSTANDING CAMPAIGN PROMISE TO LOWER DRUG PRICES

East Idaho News | July 20, 2020

news image

President Donald Trump fulfilled to a longstanding campaign promise Friday — to lower drug prices. He signed four executive orders, including ones on importing medications from Canada and basing the cost of drugs in the US on their prices in other countries — both of which progressive Democrats, including Vermont Sen. Bernie Sanders, have pushed. The efforts, which largely reaffirm the policies of the administration, are unlikely to have an effect before...

Read More

VIGILANZ LAUNCHES COVID QUICK START SOFTWARE THAT GIVES HOSPITALS CUSTOMIZABLE REAL-TIME ALERTS AND REPORTS TO MANAGE VIRAL OUTBREAKS

Prnewswire | May 21, 2020

news image

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Read More

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More

PHARMACY MARKET

Narrativa | May 19, 2021

news image

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More

East Idaho News | July 20, 2020

news image

TRUMP FULFILLED A LONGSTANDING CAMPAIGN PROMISE TO LOWER DRUG PRICES

President Donald Trump fulfilled to a longstanding campaign promise Friday — to lower drug prices. He signed four executive orders, including ones on importing medications from Canada and basing the cost of drugs in the US on their prices in other countries — both of which progressive Democrats, including Vermont Sen. Bernie Sanders, have pushed. The efforts, which largely reaffirm the policies of the administration, are unlikely to have an effect before...

Read More

Prnewswire | May 21, 2020

news image

VIGILANZ LAUNCHES COVID QUICK START SOFTWARE THAT GIVES HOSPITALS CUSTOMIZABLE REAL-TIME ALERTS AND REPORTS TO MANAGE VIRAL OUTBREAKS

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Read More

Intravacc | September 08, 2020

news image

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More